Clinical Trials
8 trialsNCT05099003 2026-05-29
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05432804 2026-05-18
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04216329 2026-01-23
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT02323880 2025-01-14
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
Phase 1 Completed
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT05952687 2024-03-27
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
St. Jude Children's Research Hospital
Phase 1 Withdrawn
NCT01607905 2023-01-26
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated